Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Necitumumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.Necitumumab is approved as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC) with cisplatin and gemcitabine.
Related Products
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.